Join CBMTG | Print Page | Contact Us | Sign In
CBMTG Webinar - Dr. Geoff Cuvelier
Tell a Friend About This EventTell a Friend
 

 Export to Your Calendar 11/6/2019
When: November 6, 2019
12:00pm PT / 3:00pm ET
Where: Canada

« Go to Upcoming Event List  

Wednesday, November 6, 2019
12:00pm PT/3:00pm ET
CME CREDIT HOURS: 1.0


Integrating Chronic GvHD Biomarkers into the Clinical Evaluation of Chronic GvHD According to the National Institutes of Health Consensus Criteria

Geoff CuvelierMD, FRCPC (CancerCare Manitoba, Winnipeg, Manitoba)
Speaker Biography:
Dr. Geoff Cuvelier is the Director of Pediatric BMT within the Manitoba Blood and Marrow Transplant program at CancerCare Manitoba and Associate Professor of Pediatrics in the Max Rady Faculty of Health Sciences, Department of Pediatrics and Child and Health at the University of Manitoba.  Dr. Cuvelier has been the lead Co-PI for the multi-institutional Applied Biomarkers of Late Effects of Childhood Cancer (ABLE) / Pediatric Blood and Marrow Transplant Consortium 1202 study that evaluated both the clinical evaluation of chronic GvHD in children, as well as prognostic cGvHD biomarkers used to predict which children are at higher risk for developing cGvHD.  
Synopsis:
In this talk, Dr. Cuvelier will discuss the evaluation of cGvHD according to the National Institutes of Health consensus criteria (applicable to both adults and children), the benefits and challenges with doing so in clinical practice, and how prognostic biomarkers present before the onset of cGvHD may be useful in the future in predicting which patients are at higher or lower risk for developing cGvHD.

Learning Objectives:
1. Have an appreciation for the National Institutes of Health Consensus Criteria (NIH-CC) for Chronic GvHD evaluation, including the difference between diagnostic, distinctive, common, and other manifestations of GVHD, and how these can be applied to the classification and evaluation of GvHD in clinical practice
2. Appreciate the benefits and challenges with the NIH-CC in evaluating cGvHD
3. Discuss how prognostic biomarkers may in the future be integrated into the risk assessment and evaluation of cGvHD

 

This website is sponsored by an unrestricted educational grant from:

Follow CBMTG